|
Vibrio cholerae (Cholera)
Read the Chapter
Sliding Table of
Contents on the left of the screen
Tables and
Figures
Table 1. In-vitro Susceptibility of O1 and O139
V. cholerae Strains Isolated from Patients Enrolled in Clinical Trials
Table 2. Antimicrobial Regimens for the Treatment
of Cholera [Download
PDF]
Table 3. Results from Studies with Fluoroquinolones
in Cholera
Vignettes
Ullman A.
Pasteur-Koch: Distinctive Ways of Thinking about Infectious Diseases.
Microbe 2007;2(8):383-387.
Ramsay MAE.
John Snow, MD: anaesthetist to the Queen of England
and pioneer epidemiologist. Proc (Bayl Univ Med Cent)
2006;19:24-28.
Rosenberg CE.
Siting Epidemic Disease: 3 Centuries of American History.
J Infect Dis 2008;197 (Suppl 1):S4-S6.
Roy SK, et al.
Zinc Supplementation in Children with Cholera in
Bangladesh: Randomised Controlled Trial.
BMJ 2008 Feb 2;336(7638):266-268.
Schild S, et al.
Ins and Outs of
Vibrio chloerae. Microbe
2008;3:131-136.
Weil A.
Clinical Outcomes in Household Contacts of Patients
with Cholera in Bangladesh. Clin Infect Dis
2009;49:1473-1479.
Review Article: Zuckerman
J, et al. The True Burden and Risk of Cholera: Implications
for Prevention and Control. The LANCET Infectious Diseases 2007;7:521-530.
Daly WJ, et al.
The Controversial and
Short-Lived Early Use of Rehydration Therapy for Cholera.
Clin Infect Dis. 2008;47(10):1315-9.
Nalin, D et al.
Oral
Therapy for Cholera:
Amino Acids Added to Electrolyte Solutions Containing Rice or Glucose.
Clin Infect Dis 2006;193:331–33. DOI: 10.1086/498873
Authors
Carlos Seas, M.D.,
Eduardo Gotuzzo, M.D.
|
www.antimicrobe.org